autosomal dominant polycystic kidney disease
Information
- Disease name
- autosomal dominant polycystic kidney disease
- Disease ID
- DOID:898
- Description
- "A polycystic kidney disease characterized by the presence of multiple cysts located_in the kidney resulting from ciliopathy that disrupts the function of primary cilium, inherited in an autosomal dominant fashion." [url:https\://en.wikipedia.org/wiki/Ciliopathy#cite_note-davenport2008-4, url:https\://rarediseases.info.nih.gov/diseases/10413/autosomal-dominant-polycystic-kidney-disease, url:https\://www.genome.gov/Genetic-Disorders/Autosomal-Polycystic-Kidney-Disease]
Disease area statistics
[No Data.]
Chromosome band
[No Data.]
Annotation
| Genes | Mutation | Description | Source | Links |
|---|
| NCT ID | Status | Phase | Summary | Start date | Completion date |
|---|---|---|---|---|---|
| NCT01670110 | Completed | Phase 2 | Pasireotide LAR in Severe Polycystic Liver Disease | August 2012 | September 2018 |
| NCT00598377 | Completed | N/A | Adrenal Functions in Autosomal Dominant Polycystic Kidney Disease | September 2006 | September 2007 |
| NCT00759369 | Completed | N/A | Water as Therapy in Autosomal Dominant Polycystic Kidney Disease (ADPKD) | September 2008 | July 2009 |
| NCT00841568 | Completed | Phase 2 | A Long-term Administration Study of OPC-41061 in Patients With Autosomal Dominant Polycystic Kidney Disease (ADPKD) [Extension of Study 156-04-001] | April 2006 | November 2010 |
| NCT01039987 | Completed | Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease | September 1999 | March 2011 | |
| NCT01210560 | Completed | Phase 2 | Dose-finding Study of New Tolvaptan Formulation in Subjects With ADPKD | October 2010 | June 2011 |
| NCT01336972 | Completed | Phase 2 | Short-term Renal Hemodynamic Effects of Tolvaptan in Subjects With Autosomal Dominant Polycystic Kidney Disease (ADPKD) | October 2010 | November 2011 |
| NCT01348035 | Completed | Efficacy Study of Water Drinking on PKD Progression. | April 2011 | January 2013 | |
| NCT01377246 | Completed | Phase 3 | Somatostatin In Patients With Autosomal Dominant Polycystic Kidney Disease And Moderate To Severe Renal Insufficiency | May 2011 | October 18, 2017 |
| NCT01451827 | Completed | Phase 2 | 8-Week Study of Tolvaptan Dose Forms in Autosomal Dominant Polycystic Kidney Disease (ADPKD) | October 2011 | July 2013 |
| NCT00414440 | Completed | Phase 4 | Efficacy, Safety and Tolerability of Everolimus in Preventing End-stage Renal Disease in Patients With Autosomal Dominant Polycystic Kidney Disease | December 2006 | October 2013 |
| NCT01810614 | Completed | N/A | A New Diet for Patients With Autosomal Dominant Polycystic Disease (ADPKD) | February 2013 | November 2014 |
| NCT02084849 | Completed | ADPKD Cohort Study | June 1998 | May 2015 | |
| NCT02119013 | Completed | Phase 2/Phase 3 | Effects of Somatostatin on ADPKD Heart | January 2009 | |
| NCT02119052 | Completed | Phase 2/Phase 3 | Effects of Somatostatin on Liver in ADPKD | January 2009 | |
| NCT02134899 | Completed | Phase 3 | The Efficacy of Everolimus in Reducing Total Native Kidney Volume in Polycystic Kidney Disease Transplanted Recipients | October 14, 2014 | November 11, 2017 |
| NCT02160145 | Completed | Phase 3 | Efficacy and Safety of Tolvaptan in Subjects With Chronic Kidney Disease Between Late Stage 2 to Early Stage 4 Due to Autosomal Dominant Polycystic Kidney Disease | May 2014 | April 18, 2017 |
| NCT02250287 | Completed | New Quantitive MRI Parameters in Assessing Kidneys of Autosomal Dominant Polycystic Kidney Disease | December 2014 | March 2016 | |
| NCT02322385 | Completed | Clinical Implications of DNA Analysis on ADPKD | January 2014 | December 31, 2016 | |
| NCT02527863 | Completed | Phase 2 | Effect of the Aquaretic Tolvaptan on Nitric Oxide System | February 2015 | August 2016 |
| NCT02933268 | Completed | N/A | High Water Intake in Polycystic Kidney Disease | September 26, 2016 | July 31, 2018 |
| NCT03487913 | Completed | Phase 2 | The ELiSA Study - Evaluation of Lixivaptan in Subjects With Autosomal Dominant Polycystic Kidney Disease | September 14, 2018 | February 11, 2020 |
| NCT03493802 | Completed | Assessment of Longitudinal Changes in Endothelial Function and Oxidative Stress in Normotensive Patients With ADPKD | November 1, 2017 | January 17, 2020 | |
| NCT03541447 | Completed | Phase 2 | Tolvaptan-Octreotide LAR Combination in ADPKD | December 12, 2018 | December 23, 2021 |
| NCT03717883 | Completed | ADPKD Alterations in Hepatic Transporter Function | September 17, 2018 | January 29, 2020 | |
| NCT03970018 | Completed | ADPKD and Peritoneal Dialysis: How Anticipate Peritoneal Pressure? | December 1, 2017 | September 1, 2018 | |
| NCT01022424 | Completed | Phase 3 | A Long-term Administration Study of OPC-41061 in Patients With Autosomal Dominant Polycystic Kidney Disease (ADPKD) (2) [Extension of Study 156-05-002] | November 2009 | July 2014 |
| NCT03901521 | Enrolling by invitation | Autosomal Dominant Polycystic Kidney Disease Somatic Mutation Biorepository | June 1, 2018 | December 31, 2028 | |
| NCT04284657 | Enrolling by invitation | Phase 2 | Pravastatin and Alkali Therapy in Patients With Autosomal Dominant Polycystic Kidney Disease | January 30, 2019 | December 31, 2025 |
| NCT05870007 | Enrolling by invitation | Phase 2 | Atorvastatin and Alkali Therapy in Patients With Autosomal Dominant Polycystic Kidney Disease | May 2023 | December 2026 |
| NCT06435858 | Not yet recruiting | Phase 4 | Short-term Effects of an SGLT2 Inhibitor on Divalent Ions in Autosomal Dominant Polycystic Kidney Disease | September 1, 2024 | December 2024 |
| NCT05190744 | Recruiting | Phase 2 | PB to Treat Hereditary Nephrogenic Diabetes Insipidus, ADPKD Treated With Tolvaptan, and Severely Polyuric Patients With Previous Lithium Administration | September 1, 2022 | December 31, 2025 |
| NCT05460169 | Recruiting | N/A | Renal Denervation in ADPKD- RDN-ADPKD Study | June 14, 2022 | May 2027 |
| NCT05521191 | Recruiting | Phase 1 | A Study of RGLS8429 in Patients With Autosomal Dominant Polycystic Kidney Disease | October 6, 2022 | June 2025 |
| NCT06065852 | Recruiting | National Registry of Rare Kidney Diseases | November 6, 2009 | December 31, 2039 | |
| NCT05193981 | Recruiting | A Study to Evaluate Homocysteine Metabolism and Endothelial Function in ADPKD | September 14, 2021 | June 2026 | |
| NCT04344769 | Recruiting | Characterization of the Nrf2 Response in Patients With Autosomal Dominant Polycystic Kidney Disease (ADPKD) | October 4, 2019 | December 2024 | |
| NCT04630613 | Recruiting | NOX4 and Related Biomarkers in ADPKD | July 21, 2020 | May 2024 | |
| NCT05288998 | Recruiting | Intrarenal Microvasculature in ADPKD | November 30, 2021 | December 2024 | |
| NCT04939935 | Recruiting | Phase 3 | Implementation of Metformin theraPy to Ease Decline of Kidney Function in Polycystic Kidney Disease (IMPEDE-PKD) | November 29, 2022 | May 2027 |
| NCT00920309 | Terminated | Phase 2/Phase 3 | Rapamycin as Treatment for Autosomal Dominant Polycystic Kidney Disease (ADPKD): The Role of Biomarkers in Predicting a Response to Therapy | June 2009 | July 2010 |
| NCT04578548 | Terminated | Phase 2 | A Study to Evaluate the Effects of GLPG2737 in Participants With Autosomal Dominant Polycystic Kidney Disease (ADPKD) | November 10, 2020 | April 4, 2023 |
| NCT02729662 | Unknown status | N/A | Efficacy of Tolvaptan on ADPKD Patients | October 1, 2016 | September 30, 2021 |
| NCT02848521 | Unknown status | A Study Measuring Quality of Life, Treatment Preference and Satisfaction of ADPKD Patients in Europe | October 2016 | March 2020 | |
| NCT02887729 | Unknown status | Analysis of Clinical and Molecular Genetic Data Influencing the Evolution and Response to Therapy of ADPKD Patients (Autosomal Dominant Polycystic Kidney Disease) | June 2010 | ||
| NCT01932450 | Unknown status | Phase 2 | Radiofrequency Ablation for ADPKD Blood Pressure and Disease Progression Control | August 2013 | July 2015 |
| NCT02187432 | Unknown status | The Eurocyst Initiative: Building a Network of ADPKD Reference Centers Across Europe | August 2013 | December 2016 | |
| NCT01988038 | Withdrawn | Repository Study of Autosomal Dominant Polycystic Kidney Disease | November 2013 | June 2016 | |
| NCT02746419 | Withdrawn | N/A | The Safety and Efficacy of Catheter-based Renal Denervation Using the Vessix™ Renal Denervation System in Autosomal Dominant Polycystic Kidney Disease (ADPKD) Patients With Severe Debilitating Pain | December 2016 | May 2020 |
- Disase is a (Disease Ontology)
- DOID:0080322
- Cross Reference ID (Disease Ontology)
- GARD:7419
- Cross Reference ID (Disease Ontology)
- ICD10CM:Q61.3
- Cross Reference ID (Disease Ontology)
- ICD9CM:753.12
- Cross Reference ID (Disease Ontology)
- MESH:D007690
- Cross Reference ID (Disease Ontology)
- NCI:C75464
- Cross Reference ID (Disease Ontology)
- ORDO:730
- Cross Reference ID (Disease Ontology)
- SNOMEDCT_US_2023_03_01:204955006
- Cross Reference ID (Disease Ontology)
- UMLS_CUI:C0022680
- Exact Synonym (Disease Ontology)
- ADPKD
- Exact Synonym (Disease Ontology)
- Congenital biliary ectasias
- Exact Synonym (Disease Ontology)
- POLYCYSTIC KIDNEY AND HEPATIC DISEASE 1